- \n
- Vyome has signed an agreement with Impetis, a TATA Enterprise, to in-license two selective JAK inhibitor assets, opening access to a large and growing ~$57B global market\u00b9<\/i><\/li>\n
- These next-generation JAK inhibitors are designed for higher selectivity, with the potential to improve safety versus earlier pan-JAK approaches<\/i><\/li>\n
- The transaction reinforces Vyome\u2019s ability to source differentiated innovation across the US\u2013India corridor and translate it into strategic value<\/i><\/li>\n
- Capital-efficient, commercialization-linked structure and future development expected through non-dilutive pathways, preserving focus on VT-1953 execution.<\/i><\/li>\n<\/ul>\n
CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–
\nVyome Holdings, Inc. (\u201cVyome\u201d) (Nasdaq: HIND) today announced the signing of an agreement with Impetis Biosciences Limited (\u201cImpetis\u201d), a TATA Enterprise, that gives it exclusive license to develop and commercialize a selective JAK 1\/3 inhibitor and a selective JAK1 inhibitor.<\/p>\n\nJanus kinase (JAK) inhibitors are immunomodulatory drugs that treat autoimmune and inflammatory conditions by blocking JAK enzymes. Several JAK inhibitors are FDA-approved to treat a wide range of disease conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, alopecia areata (baldness), atopic dermatitis (eczema), etc. However, the FDA has previously issued warnings that certain of these older-generation JAK inhibitors are associated with risks, as they are not selective.2<\/sup> Selective JAK inhibitors are designed to overcome these risks. The JAK inhibitors market size has grown rapidly in recent years, and is expected to grow from $23.56 billion in 2025 to $56.78 billion by 2030 at a compound annual growth rate (CAGR) of 19.5%.1<\/sup><\/p>\n
\n\u201cWe are delighted that Impetis trusted the Vyome team to lead the development of such valuable assets. We believe that selective JAK inhibitors are the future in immunology, and that Impetis has provided compelling preclinical data to show the clear differentiation from early generation JAK inhibitors,\u201d said Dr. Shiladitya Sengupta, Co-Founder of Vyome and Associate Professor of Medicine at Harvard Medical School. \u201cWhile we remain focused on the development of our lead asset, VT-1953 for symptoms of malignant fungating wound, a major unmet need in cancer patients, these JAK inhibitors expand our portfolio and allow us to expand to new and large immune-inflammatory therapeutic areas in the future.\u201d<\/p>\n
\n\u201cWe are building Vyome with focus and discipline in one of the most attractive segments in biotech, the immuno-inflammatory market, expected to exceed $430 billion3<\/sup> by 2034, with the JAK inhibitor segment alone representing a significant ~$57 billion opportunity,\u201d1<\/sup> said Venkat Nelabhotla, CEO of Vyome. \u201cThis transaction highlights the strength of the US\u2013India innovation corridor in sourcing high-quality assets efficiently. The transaction is structured to be very capital-efficient, with consideration tied to commercialization. Any future development will be driven through non-dilutive pathways, allowing us to remain fully focused on executing our core strategy around VT-1953.\u201d<\/p>\n
\n\u201cWe are pleased to partner with Vyome on the development of our JAK inhibitor programs,\u201d said Mr. KRS Jamwal, Chairman of Impetis. “This partnership reflects Impetis’ ongoing commitment to translating its deep preclinical portfolio into clinical value. ”<\/p>\n
About Vyome Holdings, Inc.<\/b><\/p>\n
\nBased in Cambridge, MA, Vyome\u2019s immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. To learn more, please visit www.vyometx.com<\/a><\/p>\n
About Impetis Biosciences Limited<\/b><\/p>\n
\nHeadquartered in Mumbai, India, Impetis Biosciences Limited is a company focused on advancing a portfolio of differentiated preclinical-stage drug candidates across immuno-inflammatory, immuno-oncology, and metabolic disease areas. Impetis’ pipeline is built around high value therapeutic candidates, including BTK inhibitors, a liver-selective glucokinase activator for Type 2 diabetes and novel programs targeting ROR\u03b3t and GPR91. The company progresses its assets through global licensing partnerships designed to translate pharmaceutical innovation into clinical value for patients with significant unmet medical needs.<\/p>\n
\nTo learn more, please visit www.impetisbiosciences.com<\/a><\/p>\n
Forward-Looking Statements<\/b><\/p>\n
\nCertain statements made in this press release are \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as \u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cwill,\u201d \u201cshall,\u201d \u201cmay,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cwould,\u201d \u201cpositioned,\u201d \u201cfuture,\u201d \u201cforecast,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201coutlook\u201d, and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such statements include, but are not limited to, statements contained in this press release relating to the development and commercialization of the selective JAK inhibitor assets under license from Impetis, Vyome\u2019s business strategy, and Vyome\u2019s future operating results and liquidity and capital resources outlook. Forward-looking statements are based on Vyome\u2019s current expectations and assumptions regarding Vyome\u2019s business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Vyome\u2019s actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. Vyome cautions you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, Vyome\u2019s ability to leverage the US\u2013India innovation corridor and otherwise advance VT-1953 and its other assets, including the selective JAK inhibitor assets under license from Impetis, into clinical development in a capital-efficient manner; Vyome\u2019s ability to raise capital to fund continuing operations; our ability to protect Vyome\u2019s intellectual property rights; the impact of any infringement actions or other litigation brought against Vyome; competition from other providers and products; Vyome\u2019s ability to develop and commercialize products and services; changes in government regulation; Vyome\u2019s ability to complete capital raising transactions; and other factors relating to Vyome\u2019s industry, operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause Vyome\u2019s actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. Vyome assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release, except as may be required under applicable securities law.<\/p>\n
\nVisit us on social media:<\/p>\n
Facebook
\n<\/a>
X
\n<\/a>
LinkedIn<\/a><\/p>\n1 <\/sup>https:\/\/www.researchandmarkets.com\/report\/jak-inhibitor?srsltid=AfmBOoonOb9NkQoIR8mj_k-Nb-XVnCirMY73UDt2qTp7k7IFfvbe41hi
\n<\/a>
2<\/sup>https:\/\/www.healio.com\/news\/rheumatology\/20210901\/fda-adds-black-box-warning-to-jak-inhibitors-cites-heartrelated-issues-cancer-death
\n<\/a>
3 <\/sup>https:\/\/www.datamintelligence.com\/research-report\/immunology-and-inflammatory-diseases-drugs-market<\/a><\/p>\n<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260512782680\/en\/<\/a><\/span><\/p>\n
- These next-generation JAK inhibitors are designed for higher selectivity, with the potential to improve safety versus earlier pan-JAK approaches<\/i><\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260512782680\/en\/2802622\/3\/Vyome_New_Logo_2025.jpg\"){kind=logo}
<\/td>\n<\/tr>\n